drugset / Trial / NCT02971956
Pembrolizumab in Refractory Advanced Esophageal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer. The study intervention involved in this study is: -Pembrolizumab
Timeline
- Start
- 2017-01-18
- Primary completion
- 2019-07-23
- Completion
- 2020-05-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |